The Technical Analyst
Cyclo Therapeutics, Inc. [CYTH]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Cyclo Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.69% $1.300
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 37.33 mill |
| EPS: | -1.230 |
| P/E: | -1.060 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 28.72 mill |
| Avg Daily Volume: | 0.108 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.060 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -1.060 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.144 - 1.456 ( +/- 12.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-13 | Sieger Markus | Buy | 14 004 | Common Stock |
| 2024-02-13 | Ostronic Francis Patrick | Buy | 8 703 | Common Stock |
| 2024-02-13 | Toig Randall M. | Buy | 7 516 | Common Stock |
| 2024-02-13 | Strattan Ce Rick | Buy | 6 963 | Common Stock |
| 2024-02-13 | Wong Vivien | Buy | 6 330 | Common Stock |
| INSIDER POWER |
|---|
| 50.69 |
| Last 99 transactions |
| Buy: 16 269 213 | Sell: 5 479 045 |
Forecast:
16:00 - $1.300
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.300
Forecast 2: 16:00 - $1.300
Forecast 3: 16:00 - $1.300
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.300 (5.69% ) |
| Volume | 0.0211 mill |
| Avg. Vol. | 0.108 mill |
| % of Avg. Vol | 19.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CYTH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CYTH
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Latest Press Releases
2024-03-18 09:05:00 - Press Release
Cyclo Therapeutics Reports Full Year 2023 Financial Results And Provides Business Update
Gainesville, fla.--(business wire)--cyclo therapeutics, inc. (nasdaq: cyth) (“cyclo therapeutics” or the “company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update. “we made significant progress over the course of the past year. we continue to be extremely active with the npc patient and.
2024-03-14 09:34:00 - Press Release
Cyclo Therapeutics Announces Issuance Of U.s. Patent Covering The Use Of Trappsol® Cyclo™ For The Treatment Of Alzheimer's Disease
Gainesville, fla.--(business wire)--cyclo therapeutics, inc. (nasdaq: cyth) (“cyclo therapeutics” or the “company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the united states patent and trademark office (uspto) has granted u.s. patent no. 11,925,659 titled, “methods for treating alzheimer's disease,” with claims that cover the use of trappsol® cyclo™ for.
2024-01-29 09:15:00 - Press Release
Cyclo Therapeutics Announces Allowance Of Patent Application For Treatment Of Alzheimer's Disease From The U.s. Patent And Trademark Office
Gainesville, fla.--(business wire)--cyclo therapeutics, inc. (nasdaq: cyth) (“cyclo therapeutics” or the “company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the company received a notice of allowance from the united states patent and trademark office (uspto) regarding cyclo therapeutics' u.s. patent application no. 17/289,137 titled, “methods for tre.
2023-12-27 16:15:00 - Press Release
Cyclo Therapeutics, Inc. Completes Merger With Applied Molecular Transport Inc.
Gainesville, fla.--(business wire)--cyclo therapeutics, inc. (nasdaq: cyth) (“cyclo therapeutics” or the “company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and applied molecular transport inc. (nasdaq: amti) (“amt”), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which amt will merge with cyclo therapeutics in an all-stoc.
2023-12-18 09:15:00 - Press Release
Cyclo Therapeutics Announces Positive Outcome From Type C Meeting With The U.s. Fda Discussing Trappsol® Cyclo™ Clinical Program For The Treatment Of Niemann-pick Disease Type C1
Gainesville, fla.--(business wire)--cyclo therapeutics, inc. (nasdaq: cyth) (“cyclo therapeutics” or the “company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced a positive outcome from its recent type c meeting with the u.s. food and drug administration (fda), held on thursday, december 14, 2023 to discuss a full data review of the company's trappsol® cyclo™ clinical deve.
Latest News
2023-10-05 08:05:00 - Business Wire
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Joshua Fine, Chief Financial Officer of Cyclo Therapeutics will present at the 8th Annual Dawson James Conference being held in Jupiter, FL on Thursday,.
2023-01-10 08:05:00 - Business Wire
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
GAINESVILLE, Fla.--( BUSINESS WIRE )--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 11:00 AM ET.
2022-09-07 08:05:00 - Business Wire
Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-
2022-08-08 08:05:00 - Business Wire
Cyclo Therapeutics to Present at the China NPC Association Meeting
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the 2022 China Nieman Pick Medical Exchange & Sixth Patient Association being held August 13, 2022 in Xiamen,
2022-07-21 08:05:00 - Business Wire
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it will participate at the 30th Annual NNPDF Family Support & Medical Conference in conjunction with the INPDA Biennial Meeting being held July 28-31, 2022, in Orlando, FL. “Perspectives from
2022-07-11 08:05:00 - Business Wire
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 in Boston, MA. During the session, Dr. Kjems w
2022-06-21 08:05:00 - Business Wire
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Professor Caroline Hastings, MD will present at the 2022 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 23-24, 2022. Details of the presentation are as f
2022-03-10 08:05:00 - Business Wire
Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 PM ET. In addition to the presentation, ma
2022-02-08 08:05:00 - Business Wire
Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the poster presentation of its ongoing pivotal Phase 3 study, TransportNPC™ at the 18th Annual WORLDSymposium 2022, a leading medical and scientific conference for professionals working to advance und
2022-01-20 08:05:00 - Business Wire
Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 10:00 AM ET. As part of the virtual ev